Exelixis, Inc. (NASDAQ:EXEL) Director George Poste sold 3,860 shares of the company’s stock in a transaction dated Friday, March 29th. The shares were sold at an average price of $23.89, for a total transaction of $92,215.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
NASDAQ:EXEL traded down $0.19 on Monday, reaching $23.01. The stock had a trading volume of 1,553,152 shares, compared to its average volume of 3,658,669. The firm has a market cap of $7.06 billion, a PE ratio of 16.09, a price-to-earnings-growth ratio of 0.48 and a beta of 2.21. Exelixis, Inc. has a 1-year low of $13.42 and a 1-year high of $25.31. The company has a quick ratio of 8.41, a current ratio of 8.50 and a debt-to-equity ratio of 0.01.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 EPS for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.14. Exelixis had a net margin of 80.95% and a return on equity of 48.90%. The firm had revenue of $228.60 million for the quarter, compared to analyst estimates of $188.44 million. During the same period in the previous year, the business earned $0.12 earnings per share. The company’s revenue for the quarter was up 90.4% compared to the same quarter last year. On average, research analysts expect that Exelixis, Inc. will post 1.08 EPS for the current fiscal year.
A number of analysts recently weighed in on the stock. Oppenheimer lowered their target price on shares of Exelixis from $40.00 to $31.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 13th. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Wednesday, January 9th. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Zacks Investment Research lowered shares of Exelixis from a “buy” rating to a “hold” rating in a research report on Monday, February 11th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $48.00 price target on shares of Exelixis in a research report on Friday, March 1st. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Exelixis presently has a consensus rating of “Buy” and an average price target of $29.78.
Exelixis Company Profile
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Further Reading: Commodities
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.